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In this issue of Chemistry & Biology, Zhou et al. demonstrate the possibility of effective multiple targeting of
HIV infection by using amultifunctional molecule in which an anti-CCR5 receptor aptamer (G-3) is conjugated
to an anti-TNPO3 siRNA.Despite the significant progress made
with antiretroviral treatments to suppress
viral replication to date, the human immu-
nodeficiency virus (HIV) infection remains
a significant cause of mortality globally
with 1.5 million people dying worldwide
of AIDS-related illnesses in 2013. Thera-
peutic strategies able to eradicate the
HIV infection and cure the disease with
less adverse effects are under develop-
ment, including the use of nucleic-acid
based therapeutic.
A report by Zhou et al. (2015) describes
the development of a selective and effec-
tive alternative therapy for HIV-1 infection.
To this end, the authors first generated a
highly specific aptamer for the cell surface
C-C chemokine receptor type 5, CCR5,
and then conjugated it to a siRNA for
Transportin-3 (TNPO3), proving that the
aptamer-siRNA conjugate was effective
in neutralizing the HIV-1 infection in pri-
mary peripheral blood mononuclear cells
(PBMC).
Aptamers are single-chain, short oligo-
nucleotides that are selected from high
complexity RNA (or DNA) pools through a
reiterated combinatorial process, named
systematic evolution of ligands by expo-
nential enrichment (SELEX). By folding
into specific tertiary conformations, ap-
tamers tightly bind to and inhibit protein
targets. Chemically modified aptamers
are low-immunogenic and low-toxic mole-
cules, with increased permanence in cir-
culation that makes them attractive and
effective therapeutics (Keefe et al., 2010).
In addition to providing tools to directly
inhibit the biological function of targetmol-
ecules, aptamers hold great advantages
for their use in vivo as selective delivery
agents (Esposito et al., 2014). To date, a
number of highly specific aptamers have
been generated against a number of
HIV-1viral geneproductsessential to regu-late gene expression (tat/TAR, rev/RRE),
infectivity (Gag, NCp7, gp120), and life cy-
cle (Zhou and Rossi, 2014).
In this issue, Zhou et al. (2015) gener-
ated a nucleic acid aptamer against
CCR5, named G-3, that binds to and
inhibits the receptor at high affinity
providing protection from infection by
HIV-1 R5 viruses (Berger et al., 1999; Pel-
chen-Matthews et al., 1999). Further,
Zhou et al. (2015) show that G-3-siRNA
conjugates combine the neutralizing ac-
tion of siRNA and of aptamer, thus boost-
ing the therapeutic efficacy of the two
moieties and ultimately preventing the
occurrence of resistant variants by block-
ing viral replication.
The human CCR5, a seven-transmem-
brane chemokine receptor, is the major
coreceptor for HIV-1 entry in CD4-positive
cells, making it a lead target for selective
delivery. Further, because of the natural
occurrence of the CCR5 d32 genotype
that confers resistance to HIV, CCR5 has
recently emerged as the most promising
and feasible target for antiviral therapies
that confer robust protection against
HIV-1 infection (Meanwell and Kadow,
2003).
In order to consider the development
of new therapeutic approaches that selec-
tively target the CCR5 receptor, Zhou
et al. (2015) explored the possibility of
combining the cell SELEX approach with
high throughput sequencing (HTS) tech-
nology. Cell SELEX is a variant of the
original procedure that allows one to
generate aptamers against membrane
bound proteins, such as transmembrane
receptors, imbedded in their physiological
cell context (Cerchia et al., 2009). To this
end, living whole cells expressing the anti-
gen of interest are used as a complex
target instead of purified proteins or syn-
thetic peptides. To overcome the majorChemistry & Biology 22, March 19, 2015hurdle faced when using cell SELEX, i.e.,
the more laborious identification of ap-
tamer targets, the HTS is combined with
a robust data analysis, allowing a more
rapid identification of the most promising
candidate aptamer sequences for the
target of interest (Hoinka et al., 2014).
Zhou et al. (2015) performed nine rounds
of cell SELEX on living CCR5-expressing
cells (U373-Magi-CCR5E), and the last
five rounds were analyzed by HTS. After
alignment of the more enriched se-
quences, six groups were identified (G-1
to G-6) and representative individual se-
quences from each group were analyzed
for specific binding to CCR5-expressing
human cell lines. The aptamer G-3was re-
vealed to be the best candidate, with an
apparent Kd of approximately 110 nM,
and selective internalization into the hu-
man CCR5-expressing cells has been
determined. Moreover, the G-3 aptamer
was revealed to neutralizeHIV-1 infectivity
of R5 strains both in vitro in PBMCs (170–
350 nM IC50) and on in vivo generated
human CD4+ T cells (50–250 nM IC50).
Further, in order to enhance the antiviral
potential of the aptamer, Zhou et al. (2015)
designed chimeric molecules containing
the G-3 aptamer conjugated to a TNPO3
siRNA (Thiel and Giangrande 2009; Zhou
and Rossi 2011). TNPO3, a nuclear import
receptor required for HIV-1 infection,
plays a critical role in regulating the import
of splicing factors and, thus, in cellular
homeostasis. The use of the G-3 aptamer
for CCR5-dependent delivery of TNPO3-
specific siRNA is expected to reduce the
occurrence of undesired side effects.
Zhou et al. (2015) demonstrated that the
generated chimera effectively binds and
rapidly internalizes in CCR5-expressing
cells (CEM-NKr-CCR5 and PBMCs-
CD4+), inducing TNPO3 gene silencing
after effective processing by the RNAiª2015 Elsevier Ltd All rights reserved 313
Figure 1. G-3 Aptamer and G-3-TNPO 3 Chimera Mode of Action
(A) G3 aptamer specifically binds CCR5, inhibiting HIV viral entry.
(B) G-3-TNPO3 chimera combines G-3 aptamer function with TNPO3 gene silencing, resulting in a dual
inhibitory effect on HIV-1 entry and replication.
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Previewsmachinery. In addition, treatment of
PBMC-CD4+ cells with the chimeras did
not induce the type I interferon response.
Notably, Zhou et al. (2015) demonstrated
that the combined inhibition of CCR5 (by
the aptamer) and TNPO3 gene (by the
siRNA) resulted in a pronounced dual
inhibitory effect on HIV-1 replication
(Figure 1) with a lower IC50 value (79.3 ±
21.6 nM) as compared to that obtained
with the aptamer alone (170.4 ± 47.0 nM).314 Chemistry & Biology 22, March 19, 2015These findings implicate the use of
aptamers as an alternative way for the
generation of more effective and safer
treatments for HIV-1-related diseases. In
the conjugate context, upon binding to
the cell surface receptor, CCR5, the ap-
tamers’ moiety acts as selective carrier
for the siRNA moiety and provides the
specific recognition of target cells. There-
fore, the strategy adopted has an addi-
tional advantage of being more effectiveª2015 Elsevier Ltd All rights reservedin preventing the eventual occurrence of
resistant HIV-1 variants. Given the high
versatility of aptamers, the results offer a
blueprint for the development of RNA-
guided, cell-targeted, genome-editing
strategies for the permanent knockout
viral gene expression. These delivery ap-
proaches have potentially broad applica-
bility beyond HIV-1 and can be utilized in
important noncommunicable pathologies
such as cancer.REFERENCES
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